CN107613975B - 包含聚合物纳米粒中的光敏化合物的组合物和使用该组合物的方法 - Google Patents

包含聚合物纳米粒中的光敏化合物的组合物和使用该组合物的方法 Download PDF

Info

Publication number
CN107613975B
CN107613975B CN201680027779.3A CN201680027779A CN107613975B CN 107613975 B CN107613975 B CN 107613975B CN 201680027779 A CN201680027779 A CN 201680027779A CN 107613975 B CN107613975 B CN 107613975B
Authority
CN
China
Prior art keywords
composition
cancer
sinc
polymer
pcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680027779.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107613975A (zh
Inventor
奥莱那·塔拉图拉
奥莱·塔拉图拉
亚当·阿拉尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
Original Assignee
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University filed Critical Oregon State University
Publication of CN107613975A publication Critical patent/CN107613975A/zh
Application granted granted Critical
Publication of CN107613975B publication Critical patent/CN107613975B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680027779.3A 2015-04-20 2016-04-18 包含聚合物纳米粒中的光敏化合物的组合物和使用该组合物的方法 Active CN107613975B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150125P 2015-04-20 2015-04-20
US62/150,125 2015-04-20
PCT/US2016/028113 WO2016172046A1 (en) 2015-04-20 2016-04-18 A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition

Publications (2)

Publication Number Publication Date
CN107613975A CN107613975A (zh) 2018-01-19
CN107613975B true CN107613975B (zh) 2021-08-03

Family

ID=57144184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680027779.3A Active CN107613975B (zh) 2015-04-20 2016-04-18 包含聚合物纳米粒中的光敏化合物的组合物和使用该组合物的方法

Country Status (6)

Country Link
US (1) US10646472B2 (https=)
EP (1) EP3285765B1 (https=)
JP (1) JP6769992B2 (https=)
CN (1) CN107613975B (https=)
CA (1) CA2981614C (https=)
WO (2) WO2016172046A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016172046A1 (en) * 2015-04-20 2016-10-27 Oregon State University A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition
CN107789623B (zh) * 2017-11-09 2020-12-15 福州大学 哌嗪取代硅酞菁及其在光热治疗中的应用
WO2019187569A1 (ja) * 2018-03-30 2019-10-03 東レ株式会社 生分解性を有するブロック共重合体
US20210268129A1 (en) * 2018-06-22 2021-09-02 The Governers Of The University Of Alberta Theranostic Radiophotodynamic Therapy Nanoparticles
JP7371476B2 (ja) * 2018-12-13 2023-10-31 東洋インキＳｃホールディングス株式会社 近赤外蛍光組成物および近赤外蛍光標識剤
WO2020132980A1 (zh) * 2018-12-26 2020-07-02 深圳先进技术研究院 细菌-光热纳米颗粒复合物及制备方法和应用
WO2020220085A1 (en) * 2019-05-02 2020-11-05 The University Of Sydney Peptide derivatives and conjugates thereof for treating cancer
AU2021299343A1 (en) * 2020-06-30 2023-03-02 Kenvue Brands Llc Device and method for controlling treatment for a skin condition using a tracer
US12011561B2 (en) 2020-08-03 2024-06-18 Johnson & Johnson Consumer Inc. System and method for selective application of cosmetic composition to impart undereye brightening
CN112972690B (zh) * 2021-02-22 2022-12-23 上海交通大学医学院附属第九人民医院 一种基于三角纳米金载体、制备方法及用途
CN113368235B (zh) * 2021-05-11 2022-11-15 上海师范大学 一种Gd-NGQDs/BTS@PLGA-PEG纳米材料及其制备方法和应用
US20240424147A1 (en) * 2021-10-05 2024-12-26 The Trustees Of The University Of Pennsylvania Phthalocyanine-loaded micelles for the direct visualization of tumors
CN116637209B (zh) * 2023-05-18 2024-06-07 南京溯远基因科技有限公司 一种荧光染料复合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107859A2 (en) * 2008-02-29 2009-09-03 Kyoto University Polymer nanoparticle and contrast agent for optical molecular imaging
WO2015026963A2 (en) * 2013-08-21 2015-02-26 Oregon State University Phthalocy anine-dendrimer compositions and a method of using

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
IT1391530B1 (it) * 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
WO2013012628A2 (en) 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
US8974830B2 (en) * 2012-02-23 2015-03-10 Canon Kabushiki Kaisha Particles and contrast agent including the same for optical imaging
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
WO2016172046A1 (en) * 2015-04-20 2016-10-27 Oregon State University A composition comprising a photosensitive compound in a polymeric nanoparticle, and a method of using the composition
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107859A2 (en) * 2008-02-29 2009-09-03 Kyoto University Polymer nanoparticle and contrast agent for optical molecular imaging
WO2015026963A2 (en) * 2013-08-21 2015-02-26 Oregon State University Phthalocy anine-dendrimer compositions and a method of using

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Delivery of the Photosensitizer Pc 4 in PEG–PCL Micelles for In Vitro PDT Studies;ALYSSA M. MASTER等;《JOURNAL OF PHARMACEUTICAL SCIENCES》;20100531;第99卷(第5期);第2386-2398页 *
Photophysical property of a polymeric nanoparticle loaded with an aryl benzyl ester silicon (IV) phthalocyanine;Sujuan Pan等;《PROCEEDINGS OF SPIE-Twelfth International Conference on Photonics and Imaging in Biology and Medicine (PIBM 2014)》;20140917;第9230卷;第92300T-1至92300T-5页 *
Sujuan Pan等.Photophysical property of a polymeric nanoparticle loaded with an aryl benzyl ester silicon (IV) phthalocyanine.《PROCEEDINGS OF SPIE-Twelfth International Conference on Photonics and Imaging in Biology and Medicine (PIBM 2014)》.2014,第9230卷第92300T-1至92300T-5页. *

Also Published As

Publication number Publication date
JP2018513875A (ja) 2018-05-31
US20180028496A1 (en) 2018-02-01
US10646472B2 (en) 2020-05-12
WO2019079201A2 (en) 2019-04-25
WO2016172046A1 (en) 2016-10-27
EP3285765A4 (en) 2018-12-05
CA2981614C (en) 2023-09-05
EP3285765B1 (en) 2020-04-08
CN107613975A (zh) 2018-01-19
WO2019079201A3 (en) 2019-05-31
CA2981614A1 (en) 2016-10-27
JP6769992B2 (ja) 2020-10-14
EP3285765A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CN107613975B (zh) 包含聚合物纳米粒中的光敏化合物的组合物和使用该组合物的方法
US20220347314A1 (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
Xue et al. Porphyrin-based nanomedicines for cancer treatment
Itoo et al. Nanotherapeutic intervention in photodynamic therapy for cancer
Chatterjee et al. Nanoparticles in photodynamic therapy: an emerging paradigm
Rahman et al. Photodynamic therapy for bladder cancers, a focused review
Shen et al. pH-responsive aerobic nanoparticles for effective photodynamic therapy
Ramírez-García et al. An immunoconjugated up-conversion nanocomplex for selective imaging and photodynamic therapy against HER2-positive breast cancer
Kim et al. Peptide 18-4/chlorin e6-conjugated polyhedral oligomeric silsesquioxane nanoparticles for targeted photodynamic therapy of breast cancer
WO2015026963A2 (en) Phthalocy anine-dendrimer compositions and a method of using
Wang et al. Dual-mode imaging guided multifunctional theranosomes with mitochondria targeting for photothermally controlled and enhanced photodynamic therapy in vitro and in vivo
Sun et al. Highly efficient water-soluble photosensitizer based on chlorin: synthesis, characterization, and evaluation for photodynamic therapy
Thomas et al. NIRF heptamethine cyanine dye nanocomplexes for multi modal theranosis of tumors
Komedchikova et al. Targosomes: Anti-HER2 PLGA nanocarriers for bioimaging, chemotherapy and local photothermal treatment of tumors and remote metastases
Bao et al. Design and construction of IR780-and EGCG-based and mitochondrial targeting nanoparticles and their application in tumor chemo-phototherapy
Yuan et al. Novel targeted photosensitizer as an immunomodulator for highly efficient therapy of T-cell acute lymphoblastic leukemia
Vincy et al. Optical characteristics of indocyanine green J-aggregates induced by cisplatin for phototheranostic applications
Mondal et al. Recent progress in fluorescent probes for real-time monitoring of glioblastoma
US20220008451A1 (en) Flavin adenine dinucleotide (fad) for use in the prevention and/or treatment of cancer
Mu et al. Lighting up self-quenching nanoaggregates with protein corona for simultaneous intraoperative imaging and photothermal theranostics of metastatic cancer
Shapoval et al. Temoporfin-conjugated pegylated poly (N, N-dimethylacrylamide)-coated upconversion colloid for NIR-induced photodynamic therapy of pancreatic cancer
Ren et al. Stereocomplex crystallized nanomedical system for enhanced type i pdt and synergistic chemo-phototherapy
Yang et al. Fibrin-targeted photosensitizer aggregates significantly enhance the delivery of chemotherapeutic drugs to tumor vasculature
KR102822996B1 (ko) 디셀레나이드 함유 탄화수소를 포함하고 미토콘드리아 표적형 초음파감작제가 탑재된 ros/gsh 이중 감응성 세포 외 소포체 및 이를 이용한 초음파역학 치료제
KR102574572B1 (ko) 알긴산-엽산 컨쥬게이트의 제조방법, 이로부터 제조된 알긴산-엽산 컨쥬게이트 및 이를 포함하는 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant